The U.S. Food and Drug Administration originally approved the drug in 1999, but
subsequent case reports
of abnormal behavior in adolescents who
used the
medication led the agency in 2006 to require that all packaging
of the drug include a warning label about potential neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suicide.